JP2010539256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539256A5 JP2010539256A5 JP2010524314A JP2010524314A JP2010539256A5 JP 2010539256 A5 JP2010539256 A5 JP 2010539256A5 JP 2010524314 A JP2010524314 A JP 2010524314A JP 2010524314 A JP2010524314 A JP 2010524314A JP 2010539256 A5 JP2010539256 A5 JP 2010539256A5
- Authority
- JP
- Japan
- Prior art keywords
- cell surface
- polysaccharide
- surface polysaccharide
- mixture
- polysaccharides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Chemical class 0.000 claims description 89
- 229920001282 polysaccharide Polymers 0.000 claims description 89
- 239000005017 polysaccharide Substances 0.000 claims description 89
- 210000004027 cell Anatomy 0.000 claims description 76
- 239000000203 mixture Substances 0.000 claims description 69
- 230000002163 immunogen Effects 0.000 claims description 27
- 241000193163 Clostridioides difficile Species 0.000 claims description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- 229960005486 vaccine Drugs 0.000 claims description 18
- 239000008103 glucose Substances 0.000 claims description 14
- -1 glycosyl phosphate Chemical compound 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 208000037384 Clostridium Infections Diseases 0.000 claims description 10
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims description 10
- 206010054236 Clostridium difficile infection Diseases 0.000 claims description 10
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 10
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 10
- 206010012735 Diarrhoea Diseases 0.000 claims description 10
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 10
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 10
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 10
- 229910019142 PO4 Inorganic materials 0.000 claims description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 9
- 239000010452 phosphate Substances 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 241000588807 Bordetella Species 0.000 claims description 4
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 4
- 230000003308 immunostimulating effect Effects 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 150000003214 pyranose derivatives Chemical class 0.000 claims description 4
- 229960000814 tetanus toxoid Drugs 0.000 claims description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000005847 immunogenicity Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 12
- 235000021317 phosphate Nutrition 0.000 description 5
- 238000010306 acid treatment Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97141107P | 2007-09-11 | 2007-09-11 | |
| US60/971,411 | 2007-09-11 | ||
| PCT/CA2008/001593 WO2009033268A1 (en) | 2007-09-11 | 2008-09-11 | Novel polysaccharide immunogens from clostridium difficile |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539256A JP2010539256A (ja) | 2010-12-16 |
| JP2010539256A5 true JP2010539256A5 (enExample) | 2012-11-01 |
| JP5501969B2 JP5501969B2 (ja) | 2014-05-28 |
Family
ID=40451511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010524314A Active JP5501969B2 (ja) | 2007-09-11 | 2008-09-11 | クロストリジウム・ディフィシル由来の多糖免疫原 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8597663B2 (enExample) |
| EP (2) | EP2195018B1 (enExample) |
| JP (1) | JP5501969B2 (enExample) |
| CN (1) | CN101896197B (enExample) |
| AU (1) | AU2008299536B2 (enExample) |
| CA (2) | CA2941174C (enExample) |
| ES (2) | ES2534671T3 (enExample) |
| NZ (1) | NZ583750A (enExample) |
| WO (1) | WO2009033268A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2534671T3 (es) * | 2007-09-11 | 2015-04-27 | University Of Guelph | Inmunógenos polisacáridos de la Clostridium difficile |
| WO2012085668A2 (en) * | 2010-12-24 | 2012-06-28 | Novartis Ag | Compounds |
| WO2012119769A1 (en) | 2011-03-08 | 2012-09-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. | Oligosaccharides and oligosaccharide-protein conjugates derived from clostridium difficile polysaccharide ps-ii, methods of synthesis and uses thereof, in particular as a vaccine |
| US9815889B2 (en) | 2011-08-02 | 2017-11-14 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Antibodies for prevention and treatment of diseases caused by clostridium difficile |
| EP2554549A1 (en) | 2011-08-02 | 2013-02-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Oligosaccharides and oligosaccharides-protein conjugates derived from clostridium difficile polysaccharide PS-I, methods of synthesis and uses thereof, in particular as vaccines and diagnostic tools |
| WO2013071409A1 (en) | 2011-11-18 | 2013-05-23 | National Research Council Of Canada (Nrc) | Clostridium difficile lipoteichoic acid and uses thereof |
| WO2014013375A1 (en) | 2012-07-16 | 2014-01-23 | Pfizer Inc. | Saccharides and uses thereof |
| CN106659799B (zh) * | 2014-07-25 | 2020-07-17 | 碧奥辛斯有限责任公司 | 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗 |
| MX2020006270A (es) * | 2017-12-19 | 2020-09-14 | Univ Alberta | Glucanos de superficie de clostridium perfringens y usos de los mismos. |
| US10933126B2 (en) | 2018-05-03 | 2021-03-02 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile immunogenic compositions and methods of use |
| JP2022513077A (ja) * | 2018-11-16 | 2022-02-07 | マトリバックス，インコーポレーテッド | クロストリジウム・ディフィシル多成分ワクチン |
| US12187756B2 (en) | 2018-11-22 | 2025-01-07 | Idorsia Pharmaceuticals Ltd | Stable vaccine against Clostridium difficile |
| WO2026013167A1 (en) | 2024-07-11 | 2026-01-15 | Idorsia Pharmaceuticals Ltd | Pharmaceutical composition comprising clostridioides difficile vaccine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5562909A (en) | 1993-07-12 | 1996-10-08 | Massachusetts Institute Of Technology | Phosphazene polyelectrolytes as immunoadjuvants |
| GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| US20030072774A1 (en) | 1994-06-10 | 2003-04-17 | Diane M. Gajewczyk | Proteinaceous adjuvants |
| US6019982A (en) | 1994-08-26 | 2000-02-01 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
| FR2726764B1 (fr) | 1994-11-14 | 1997-01-31 | Pasteur Merieux Serums Vacc | Adjuvant pour composition vaccinale |
| US6284884B1 (en) | 1995-06-07 | 2001-09-04 | North American Vaccine, Inc. | Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof |
| EP1073667A2 (en) * | 1998-04-28 | 2001-02-07 | Galenica Pharmaceuticals, Inc. | Polysaccharide-antigen conjugates |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| FI20011403A7 (fi) * | 2001-06-29 | 2002-12-30 | Carbion Oy | Menetelmä ja koostumukset vatsan sairauksien hoitoon |
| US7541043B2 (en) * | 2002-01-16 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine for protection against Shigella sonnei disease |
| CA2623400C (en) | 2005-09-21 | 2015-04-07 | Patricia Guerry | Immunogenic capsule composition for use as a vaccine component against campylobacter jejuni |
| GB0713880D0 (en) * | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| ES2534671T3 (es) * | 2007-09-11 | 2015-04-27 | University Of Guelph | Inmunógenos polisacáridos de la Clostridium difficile |
-
2008
- 2008-09-11 ES ES13183746.0T patent/ES2534671T3/es active Active
- 2008-09-11 CN CN2008801155182A patent/CN101896197B/zh active Active
- 2008-09-11 AU AU2008299536A patent/AU2008299536B2/en not_active Ceased
- 2008-09-11 US US12/676,369 patent/US8597663B2/en active Active
- 2008-09-11 ES ES08800297.7T patent/ES2528648T3/es active Active
- 2008-09-11 WO PCT/CA2008/001593 patent/WO2009033268A1/en not_active Ceased
- 2008-09-11 CA CA2941174A patent/CA2941174C/en active Active
- 2008-09-11 CA CA2698157A patent/CA2698157C/en active Active
- 2008-09-11 EP EP08800297.7A patent/EP2195018B1/en active Active
- 2008-09-11 EP EP13183746.0A patent/EP2674169B1/en active Active
- 2008-09-11 JP JP2010524314A patent/JP5501969B2/ja active Active
- 2008-09-11 NZ NZ583750A patent/NZ583750A/en active IP Right Revival
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539256A5 (enExample) | ||
| Barcelos et al. | Current status of biotechnological production and applications of microbial exopolysaccharides | |
| AU2008299536B2 (en) | Novel polysaccharide immunogens from clostridium difficile | |
| CA2450203A1 (en) | Capsular polysaccharide solubilisation and combination vaccines | |
| RU2016127123A (ru) | Капсульные полисахариды Streptococcus pneumoniae и их конъюгаты | |
| RU2014134288A (ru) | Иммуногенная композиция | |
| MXPA05011110A (es) | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos. | |
| JP2002528558A (ja) | 遺伝的に修飾されたグラム陰性細菌由来の低毒性ｌｐｓ | |
| TW200514569A (en) | Vaccine composition | |
| JP2011504487A5 (enExample) | ||
| US20240366743A1 (en) | Multivalent Pneumococcal Glycoconjugate Vaccines Containing Emerging Serotype 24F | |
| WO2014009971A3 (en) | Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof | |
| JP2011504535A5 (enExample) | ||
| KR20230164108A (ko) | E. coli O18 생물접합체의 생산 | |
| WO2023161817A1 (en) | Methods for incorporating azido groups in bacterial capsular polysaccharides | |
| JP2016513747A5 (enExample) | ||
| CN102626515B (zh) | b型流感嗜血杆菌多糖结合疫苗活化方法 | |
| KR102388325B1 (ko) | 저분자화 PRP를 사용한 Hib 컨쥬게이트 백신의 제조방법 | |
| CN101014698A (zh) | 作为多种疫苗候选物的保守性内核脂多糖表位 | |
| AU2018204255B2 (en) | Immunogenic composition against Campylobacter jejuni | |
| HUP0700044A2 (en) | Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates | |
| RU2407792C1 (ru) | СПОСОБ ПОЛУЧЕНИЯ IgAl-ПРОТЕАЗЫ ИЗ КУЛЬТУРЫ NEISSERIA MENINGITIDIS СЕРОГРУППЫ А И ИММУНОГЕННЫЙ ПРЕПАРАТ НА ЕЕ ОСНОВЕ | |
| RU2636454C2 (ru) | Вакцина для профилактики некробактериоза животных и способ её получения | |
| RU2520078C1 (ru) | СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD | |
| RU2590596C1 (ru) | Вакцина для профилактики некробактериоза животных и способ её получения |